CompletedPhase 2

A Study of Bone Marrow Transplantation Using Fully-Matched Relatives as Donors for Patients With Hematological Malignancies

United States47 participantsStarted 2008-04-10

Plain-language summary

This research study uses a drug called cyclophosphamide to decrease the incidence of GVHD in matched sibling hematopoietic stem cell transplant. In doing so, the goal of the study is to increase overall survival.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Any patient with a hematologic or oncologic diagnosis in which allogeneic HSCT is thought to be beneficial, and in whom front-line therapy has already been applied. Patients will be considered high-risk if they have any of the following:
✓. Age \> 50 years
✓. ECOG Performance status of \<2
✓. Acute leukemia: requiring more than one chemotherapy regimen to obtain 1st CR; second or greater CR, 1st relapse; any ph+ ALL
✓. CML 2nd chronic phase, accelerated phase, or blastic phase
✓. MDS with IPS of Intermediate 2 or greater
✓. Any myeloproliferative disorder
✓. Hodgkin lymphoma: relapsed, refractory, or primary induction failure

Exclusion criteria

✕. ECOG performance status of 3 or 4.
✕. HIV positive
✕. Active involvement of the central nervous system with malignancy
✕. Psychiatric disorder that would preclude patients from signing an informed consent
✕. Pregnancy
✕. Patients with life expectancy of \< 6 months for reasons other than their underlying hematologic/oncologic disorder.

What they're measuring

Number of Patients With Overall Survival

Timeframe: 1 Year after transplant

Trial details

NCT IDNCT01315132

SponsorSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2018-09-19

Results submitted2019-09-04

View on ClinicalTrials.gov More Hematological Malignancies trials